Weight-Loss drug for kids? new trial tests liraglutide in children as young as 6

NCT ID NCT04775082

Ongoing Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study tests whether a daily injection of liraglutide (3.0 mg) can help children aged 6 to 12 with obesity lose weight. Over 56 weeks, 78 children will receive either liraglutide or a placebo, along with counseling on diet and exercise. The main goal is to see how much their body mass index (BMI) changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liraglutide
What this could lead to: If successful, this could provide a new medication option to help children with obesity lose weight, potentially reducing future health risks.
What could go wrong: This is a relatively small Phase 3 trial (78 children). Liraglutide may cause side effects like nausea or vomiting, and weight loss may not be sustained long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

Barry J. Reiner, MD LLC

Baltimore, Maryland, 21229, United States
CUF-Porto

Porto, 4100-180, Portugal
Centro Hospitalar Lisboa Norte

Lisbon, 1649-035, Portugal
Children's Hospital Colorado

Denver, Colorado, 80045, United States
Consultorio de Endocrinología y Pediatría

Puebla City, 72190, Mexico
Endolife Specialty Hospitals

Guntur, Andhra Pradesh, 522001, India
FSBI 'I.I. Dedov National Medical Research Center of Endocrinology' of the MH of Russia

Moscow, 117292, Russia
Hospital CUF Porto S.A.

Porto, 4100-180, Portugal
Hospital Putrajaya

Putrajaya, 62250, Malaysia
Hospital da Luz

Lisbon, 1500-650, Portugal
Hospital da Luz Lisboa, S.A.

Lisbon, 1500-650, Portugal
Kantonsspital Olten

Olten, 4600, Switzerland
Kinderspital Endokrinologie, Zürich

Zurich, 8032, Switzerland
Mamc & Lnjp

New Delhi, 110002, India
NSMU paediatric clinic

Novosibirsk, 630048, Russia
Pennington Biom Res Ctr

Baton Rouge, Louisiana, 70808, United States
PriMed Clinical Research

Dayton, Ohio, 45419, United States
Rambam MC - Department of Pediatrics A

Haifa, 31096, Israel
Samara Regional Children Clinical Hospital n.a. N.N. Ivanova

Samara, 443079, Russia
Schneider MC - Endrocrinology and Diabetes

Petah Tikva, 49202, Israel
Siberian State Medical University

Tomsk, 634050, Russia
Solaris Clinical Research

Meridian, Idaho, 83646, United States
TMC Hlthcr Clin Res Office

Tucson, Arizona, 85712, United States
UBMD Peds-Div of Endo/Diabetes

Buffalo, New York, 14203, United States
ULS De Santo António, E.P.E. - Hospital de Santo António

Porto, 4099-001, Portugal
UPMC Child Hosp-Pittsburgh

Pittsburgh, Pennsylvania, 15224, United States
UZ Brussel

Brussels, 1090, Belgium
UZ Leuven - Kindergeneeskunde

Leuven, 3000, Belgium
Unidade De Santa Maria E.P.E. - Hospital de Santa Maria

Lisbon, 1649-035, Portugal
Unidade Local de Saúde de Santo António, E.P.E

Porto, 4099-001, Portugal
University Malaya Medical Centre

Lembah Pantai, Kuala Lumpur, 59100, Malaysia
University of Minnesota_CPOM

Minneapolis, Minnesota, 55414, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.